Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia.
暂无分享,去创建一个
[1] J. Shimada,et al. Post-Marketing Surveillance of the Safety of Levofloxacin in Japan , 2007, Chemotherapy.
[2] P. O'Gaora,et al. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. , 2006, The Journal of antimicrobial chemotherapy.
[3] R. Theriault,et al. Once daily, oral, outpatient quinolone monotherapy for low‐risk cancer patients with fever and neutropenia , 2006, Cancer.
[4] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic data , 1983, Journal of Pharmacokinetics and Biopharmaceutics.
[5] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[6] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.
[7] T. Ozawa,et al. Clostridium difficile infection associated with levofloxacin treatment. , 2002, Tennessee medicine : journal of the Tennessee Medical Association.
[8] J. Domagala,et al. Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG andStaphylococcus aureus , 1999, Antimicrobial Agents and Chemotherapy.
[9] W. Craig,et al. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] D. Fish,et al. The Clinical Pharmacokinetics of Levofloxacin , 1997, Clinical pharmacokinetics.
[11] Y. Tanigawara,et al. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. , 1995, Biological & pharmaceutical bulletin.
[12] M. Nakashima,et al. Phase I Study of Levofloxacin, (S)-(-)-Ofloxacin. , 1992 .
[13] 厚他 斎藤. 慢性下気道感染症に対するLevofloxacin (LVFX) の用量比較臨床試験 , 1992 .
[14] K. Ichikawa,et al. [Pharmacokinetic and clinical evaluation of levofloxacin in obstetrics and gynecology]. , 1992, The Japanese journal of antibiotics.
[15] T. Tsukamoto,et al. [Clinical efficacy of levofloxacin (LVFX) single-dose therapy in female acute uncomplicated cystitis]. , 1992, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.
[16] S. Kamidono,et al. DOSE-FINDING STUDY ON LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTIONS , 1992 .